Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder

International Journal of Neuropsychopharmacology

Volumn 12, Issue 4, 2009, Pages 447-458

  Kauer Sant'Anna, Marcia ^a,b   Kapczinski, Flvio ^c   Andreazza, Ana C ^a,b   Bond, David J ^a   Lam, Raymond W ^a   Young, L Trevor ^a   Yatham, Lakshmi N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

BDNF; Bipolar disorder; Cytokines; First episode; Interleukins; TNF

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; MOOD STABILIZER; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MANIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ADOLESCENT; CASE CONTROL STUDY; METABOLISM; ONSET AGE; SOCIOECONOMICS;

ADOLESCENT; ADULT; AGE OF ONSET; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MALE; SOCIOECONOMIC FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 67649205987     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009310     Document Type: Article

References (61)

1. Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, Graos MM, Carvalho RF, Carvalho AP, Duarte CB (2005). Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death and Differentiation 12, 1329-1343.
2. APA (2000). Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
3. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS (1998). A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biological Psychiatry 44, 88-97.
4. Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, Yatham LN, Yung A, McGorry P (2007). Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disorders 9, 671-678.
5. Brietzke B, Kapczinski F (2008). TNF-a as a molecular target in bipolar disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 1355-1361.
6. Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN (2004). Cytokine production in bipolar affective disorder patients under lithium treatment. Journal of Affective Disorders 82, 309-313.
7. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, Nociti V, Tonali PA, Mirabella M (2005). Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scandinavian Journal of Immunology 62, 176-182.
8. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA, Santin A, Kapczinski F (2006). Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neuroscience Letters 398, 215-219.
9. Duman RS, Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. Biological Psychiatry 59, 1116-1127.
10. Frey BN, Andreazza AC, Ceresér KM, Martins MR, Valvassori SS, Réus GZ, Quevedo J, Kapczinski F (2006). Effects of mood stabilizers onhippocampus BDNF levels in an animal model of mania. Life Sciences 79, 281-286.
11. Furuno T, Nakanishi M (2006). Neurotrophic factors increase tumor necrosis factor-alpha-induced nuclear translocation of NF-kappaB in rat PC12 cells. Neuroscience Letters 392, 240-244.
12. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J (1989). Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. New England Journal of Medicine 321, 1489-1493.
13. Hashimoto K, Shimizu E, Iyo M (2004). Critical role of brain-derived neurotrophic factor in mood disorders. Brain Research. Brain Research Reviews 45, 104-114.
14. Imamura K, Hishikawa N, Ono K, Suzuki H, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2005). Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of lewy body disease brains. Acta Neuropathologica 109, 141-150.
15. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, Kauer-Sant'Anna M, Grassi-Oliveira R, Post RM (2008). Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neuroscience and Biobehavioral Reviews 32, 675-692.
16. Karege F, Schwald M, Cisse M (2002). Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neuroscience Letters 328, 261-264.
17. Kessing LV, Andersen PK, Mortensen PB (1998). Predictors of recurrence in affective disorder. A case register study. Journal of Affective Disorders 49, 101-108.
18. Kim YK, Jung HG, Myint AM, Kim H, Park SH (2007). Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. Journal of Affective Disorders 104, 91-95.
19. Kupka RW, Breunis MN, Knijff E, Ruwhof C, Nolen WA, Drexhage HA (2002). Immune activation, steroid resistancy and bipolar disorder. Bipolar Disorders 4 (Suppl. 1), 73-74.
20. Lang UE, Hellweg R, Seifert F, Schubert F, Gallinat J (2007). Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biological Psychiatry 62, 530-535.
21. Larson SJ, Dunn AJ (2001). Behavioral effects of cytokines. Brain, Behavior, and Immunity 15, 371-387.
22. Laske C, Eschweiler GW (2006). Brain-derived neurotrophic factor: from nerve growth factor to modulator of brain plasticity in cognitive processes and psychiatric diseases. Der Nervenarzt 77, 523-537.
23. Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K (2006). Stage-dependent BDNF serum concentrations in alzheimer's disease. Journal of Neural Transmission 113, 1217-1224.
24. Lopez-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM (2002). Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biological Psychiatry 52, 93-100.
25. Lyoo IK, Kim MJ, Stoll AL, Demopulos CM, Parow AM, Dager SR, Friedman SD, Dunner DL, Renshaw PF (2004). Frontal lobe gray matter density decreases in bipolar I disorder. Biological Psychiatry 55, 648-651.
26. Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee JY, Kim SJ, Kim N, Dunner DL, Renshaw PF (2006). Regional cerebral cortical thinning in bipolar disorder. Bipolar Disorders 8, 65-74.
27. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, Souza DO, Portela LV, Gentil V (2007). Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biological Psychiatry 61, 142-144.
28. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (2000). Caspase activities and tumor necrosis factor receptor R1 level are elevated in the substantia nigra from parkinsonian brain. Journal of Neural Transmission 107, 335-341.
29. Monteleone P, Serritella C, Martiadis V, Maj M (2008). Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disorders 10, 95-100.
30. Murphy PG, Borthwick LA, Altares M, Gauldie J, Kaplan D, Richardson PM (2000). Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons. European Journal of Neuroscience 12, 1891-1899.
31. Nagatsu T, Mogi M, Ichinose H, Togari A (2000). Changes in cytokines and neurotrophins in parkinson's disease. Journal of Neural Transmission (Suppl.) 60, 277-290.
32. O'Brien SM, Scully P, Scott LV, Dinan TG (2006). Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. Journal of Affective Disorders 90, 263-267.
33. Ohgoh M, Kimura M, Ogura H, Katayama K, Nishizawa Y (1998). Apoptotic cell death of cultured cerebral cortical neurons induced by withdrawal of astroglial trophic support. Experimental Neurology 149, 51-63.
34. Ortiz-Dominguez A, Hernandez ME, Berlanga C, Gutierrez-Mora D, Moreno J, Heinze G, Pavon L (2007). Immune variations in bipolar disorder: phasic differences. Bipolar Disorders 9, 596-602.
35. Palomino A, Gonzalez-Pinto A, Aldama A, Gonzalez-Gomez C, Mosquera F, Gonzalez-Garcia G, Matute C (2007). Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. Schizophrenia Research 95, 174-178.
36. Phillips ML, Drevets WC, Rauch SL, Lane R (2003). Neurobiology of emotion perception. I: The neural basis of normal emotion perception. Biological Psychiatry 54, 504-514.
37. Post RM (2007a). Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neuroscience and Biobehavioral Reviews 31, 858-873.
38. Post RM (2007b). Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. Journal of Psychiatric Research 41, 979-990.
39. Rajkowska G (2002). Cell pathology in bipolar disorder. Bipolar Disorders 4, 105-116.
40. Rajkowska G, Halaris A, Selemon LD (2001). Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biological Psychiatry 49, 741-752.
41. Rapaport MH, Manji HK (2001). The effects of lithium on ex vivo cytokine production. Biological Psychiatry 50, 217-224.
42. Schuepbach D, Novick D, Haro JM, Reed C, Boeker H, Noda S, Angst J, Hell D, EMBLEM Advisory Board (2008). Determinants of voluntary vs. involuntary admission in bipolar disorder and the impact of adherence. Pharmacopsychiatry 41, 29-36.
43. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, Katlama C, Bricaire F, Duyckaerts C, Hauw JJ (1997). Tumor necrosis factor-alpha, microglia and astrocytes in AIDS dementia complex. Acta Neuropathologica 93, 508-517.
44. Shaltiel G, Chen G, Manji HK (2007). Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Current Opinion in Pharmacology 7, 22-26.
45. Sheehan DV, LecrubierY, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998). The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 (Suppl. 20), 22-33.
46. Shimizu E, Hashimoto K, Okamura N (2003). Alterations of serum levels of brain-derived neurotrophic factor in depressed patients with or without antidepressants. Biological Psychiatry 54, 70-75.
47. Strakowski SM, DelBello MP, Zimmerman ME, Getz GE, Mills NP, Ret J, Shear P, Adler CM (2002). Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. American Journal of Psychiatry 159, 1841-1847.
48. Su KP, Leu SJ, Yang YY, Shen WW, Chou YM, Tsai SY (2002). Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. Journal of Affective Disorders 71, 205-209.
49. Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T (2006). Roles of glia-derived cytokines on neuronal degeneration and regeneration. Annals of the New York Academy of Sciences 1088, 219-229.
50. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD (1999). Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. American Journal of Psychiatry 156, 1264-1266.
51. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A (2006). Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. Journal of Biological Chemistry 281, 21362-21368.
52. Tobinick E, Gross H, Weinberger A, Cohen H (2006). TNF-alpha modulation for treatment of alzheimer's disease: a 6-month pilot study. Medscape General Medicine 8, 25.
53. Tohen M, Waternaux CM, Tsuang MT (1990). Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Archives of General Psychiatry 47, 1106-1111.
54. Torres IJ, Boudreau VG, Yatham LN (2007). Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatrica Scandinavica (Suppl.) 434, 17-26.
55. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI (2004). Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the stanley neuropathology consortium. Schizophrenia Research 67, 269-275.
56. Williams JB (1988). A structured interview guide for the hamilton depression rating scale. Archives of General Psychiatry 45, 742-747.
57. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, AldaM,BaruchP,etal. (2005).Canadiannetwork formood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders 7 (Suppl. 3), 5-69.
58. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S, Guidelines Group (2006). Canadian network for mood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disorders 8, 721-739.
59. Yatham LN, Lyoo IK, Liddle P, Renshaw PF, Wan D, Lam RW, Hwang J (2007). A magnetic resonance imaging study of mood stabilizer- and neuroleptic-naive first-episode mania. Bipolar Disorders 9, 693-697.
60. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429-435.
61. Zarate CA, Quiroz J, Payne J, Manji HK (2002). Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacology Bulletin 36, 35-83.